CTRI/2020/06/025910已完成未知
Safety And Efficacy Of Sofosbuvir And Daclatasvir In Children And Adolescents With Thalassemia With Chronic HCV Infection A Pilot Study
Riten Kumar Samadder0 个研究点目标入组 70 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All Patients Of Chronic Hepatitis C In Thalassemic Patient With 6 To 18 Years of Age With Any Level Of Detectable HCV RNA Is To Be Included In The Study
- •Patients Could Be Either Treatment Naive Or Interferon Experienced
排除标准
- •The Legal Guardians/Parents Of The Patients Who Are Not Willing To Give Written Consent
- •Patients Who Are HIV Positive
- •Patients Who Were HBsAg Positive
- •Patient With HCV RNA Below Detection Level At Entry To The Trial
- •Patient With Associated Tuberculosis Or Malignancy
- •Presence of Cirrhosis
- •Presence Of Any Major Comorbidities Like Heart Failure
研究者
相似试验
招募中
2 期
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
已完成
不适用
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.IRCT20170614034526N3Jinnah Hospital, Lahore36
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
招募中
1 期
Safety of Sofosbuvir /Daclatasvir in outpatients with COVID-19IRCT20200128046294N3Tehran University of Medical Sciences50
已完成
3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000